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ABSTRACT
Background: Metabolomics may unravel important biological
pathways involved in the pathophysiology of childhood obesity.
Objectives: We aimed to 1) identify metabolites that differ signif-
icantly between nonobese and obese Hispanic children; 2) collapse
metabolites into principal components (PCs) associated with obesity
and metabolic risk, specifically hyperinsulinemia, hypertriglyceridemia,
hyperleptinemia, and hyperuricemia; and 3) identify metabolites asso-
ciated with energy expenditure and fat oxidation.
Design: This trial was a cross-sectional observational study of me-
tabolomics by using gas chromatography–mass spectrometry and
ultrahigh-performance liquid chromatography–tandem mass spec-
trometry analyses performed on fasting plasma samples from 353
nonobese and 450 obese Hispanic children.
Results: Branched-chained amino acids (BCAAs) (Leu, Ile, and
Val) and their catabolites, propionylcarnitine and butyrylcarnitine, were
significantly elevated in obese children. Strikingly lower lysolipids and
dicarboxylated fatty acids were seen in obese children. Steroid deriva-
tives were markedly higher in obese children as were markers of in-
flammation and oxidative stress. PC6 (BCAAs and aromatic AAs) and
PC10 (asparagine, glycine, and serine) made the largest contributions to
body mass index, and PC10 and PC12 (acylcarnitines) made the largest
contributions to adiposity. Metabolic risk factors and total energy ex-
penditure were associated with PC6, PC9 (AA and tricarboxylic acid
cycle metabolites), and PC10. Fat oxidation was inversely related to
PC8 (lysolipids) and positively related to PC16 (acylcarnitines).
Conclusions: Global metabolomic profiling in nonobese and obese
children replicates the increased BCAA and acylcarnitine catabo-
lism and changes in nucleotides, lysolipids, and inflammation
markers seen in obese adults; however, a strong signature of reduced
fatty acid catabolism and increased steroid derivatives may be
unique to obese children. Metabolic flexibility in fuel use observed
in obese children may occur through the activation of alternative
intermediary pathways. Insulin resistance, hyperleptinemia, hyper-
triglyceridemia, hyperuricemia, and oxidative stress and inflamma-
tion evident in obese children are associated with distinct metabolomic
profiles. Am J Clin Nutr 2015;102:256–67.
Keywords: acylcarnitines, amino acids, carbohydrates, lipids,
nucleotides
INTRODUCTION
Childhood obesity is associated with increased risk of glucose
intolerance, hypertension, dyslipidemia, insulin resistance,
chronic inflammation, hyperuricemia and nonalcoholic fatty liver
disease (1). Although genetics, diet, physical activity, and other
behavioral and environmental factors contribute to these ail-
ments, the metabolic pathways that underlie the development and
progression of these metabolic diseases remain uncertain.
Metabolomics, which is the measurement of low–molecular
weight metabolites such as nutrient intermediates, hormones,
and other signaling molecules, may provide insight into their
cause.
Metabolomic studies in obese adults have consistently in-
dicated a metabolomic profile associated with insulin resistance,
diabetes, and cardiovascular disease (2–7). A pattern of in-
creased plasma concentrations of branched-chain amino acids
(BCAAs)8 (Val, Leu, and Ile), aromatic amino acids (AAs) (Phe
and Tyr), C3 and C5 acylcarnitines, and Glx and Ala was shown
to be strongly associated with insulin resistance. The accumu-
lation of incompletely oxidized lipid species in the mitochondria
also has been implicated in the development of insulin resistance
(3, 4, 6).
Metabolomic profiling in obese and nonobese children has
been performed with conflicting findings (8–11). In a comparison
study of normal-weight and obese adolescents, there was little
evidence of defective fatty acid or AA metabolism associated
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with obesity (8). In another study, increased plasma AA con-
centrations (BCAAs, Phe, Met, His, Arg, Ser, Gly, and acyl-
carnitines) were positively associated with b cell function
relative to insulin sensitivity in contrast to findings in adults
(11). Acylcarnitines (12:1 and 16:1) were higher, and 3 AAs
(Glu, Met, and Pro) and acyl-alkyl phosphatidylcholines (34–38)
and lysophosphatidylcholines (18:1, 18:2, and 20:4) were lower,
in obese children, which were indicative of oxidative stress and
changes in b oxidation and sphingomyelin metabolism (9).
Higher concentrations of BCAAs and related intermediates C3
and C5 acylcarnitines, androgens, and large neutral AAs were
seen in obese children (10). Thus, existing data are equivocal as
to whether metabolomic alterations or adaptive metabolic plas-
ticity occurs in children with obesity.
Because of the potential of metabolomics to reveal important
biological pathways involved in the pathophysiology of child-
hood obesity and to reconcile the existing conflicting evidence in
children, we applied nontargeted metabolomic profiling in 803
Hispanic children enrolled in the Viva la Familia Study (12).
Obese children in this cohort were shown to be at increased risk of
glucose intolerance, hypertension, dyslipidemia, insulin re-
sistance (13), chronic inflammation (14), hyperuricemia (15) and
nonalcoholic fatty liver disease (16). Our research aims were to 1)
identify metabolites that differ significantly between nonobese
and obese Hispanic children; 2) collapse metabolites into
principal components (PCs) associated with obesity and meta-
bolic risk, specifically, hyperinsulinemia, hypertriglyceridemia,
hyperleptinemia, and hyperuricemia; and 3) identify metabolites
associated with energy expenditure and fat oxidation.
METHODS
Subjects and design
Global metabolomic profiling was performed on fasting
plasma samples from 803 Hispanic children enrolled in the Viva
la Familia Study, which was a cross-sectional observational study
designed to identify genetic variants influencing childhood
obesity and its comorbidities. Eligibility and enrollment were
described in detail elsewhere (12). Family recruitment and
phenotyping were conducted in 2000–2005 in Houston, Texas.
All enrolled children provided written assent, and parents gave
written informed consent. The protocol was approved by the
Institutional Review Boards for Human Subject Research for
Baylor College of Medicine and Affiliated Hospitals and for the
Texas Biomedical Research Institute.
Methods
In-depth phenotyping included anthropometric measures and
body composition, 24-h calorimetry, and fasting blood sampling
for clinical biochemistries. Anthropometric measures were per-
formed by using standardized techniques according to Lohman
et al. (17). Body composition, including fat-free mass (FFM)
and fat mass (FM), was determined by using dual-energy X-ray
absorptiometry. Methods used to measure fasting blood bio-
chemistries were described elsewhere (12–14, 18). Room res-
piration calorimetry was used to make 24-h measurements of
energy expenditure, the respiratory quotient (RQ), and substrate
oxidation (19).
Metabolomic profiling
Fasting EDTA plasma samples were taken from 803 Hispanic
children and stored at 2808C. Analyses were performed on the
plasma samples and replicate samples created from a large pool
of extensively characterized human plasma (MTRX3). Non-
targeted metabolomic profiling was conducted by using the
following 3 independent platforms: ultra-HPLC–tandem mass
spectrometry optimized for basic species, ultra-HPLC–tandem mass
spectrometry optimized for acidic species, and gas chromatography–
mass spectrometry. Metabolomic analyses were performed as
outlined previously (20).
The original data set consisted of 409 named metabolites. Of
the original 409 named metabolites, we excluded 77 metabolites
that were missing values for .40% of participants and 28 xe-
nobiotics; hence, our final data set was comprised of 304 named
metabolites.
Block normalization was performed on the original raw ion
intensities to correct for variation that resulted from instrument
interday tuning differences. Essentially, raw area counts for each
compound in run-day blocks were rescaled to set medians to
equal one. Any missing values were assumed to be below the
limits of detection, and these values were imputed with the
compound minimum (minimum value imputation).
To test for data reliability, a subset of 40 plasma samples were
reanalyzed. Of the original 304 metabolites, 11.8% of metabo-
lites in nonobese subjects and 8.9% of metabolites in obese
subjects were shown to be significantly different between runs;
however, the mean (6SD) intraclass correlation for these me-
tabolites was 0.82 6 0.17.
Statistical analysis
Numerical methods (i.e., skewness, kurtosis, and the Shapiro-
Wilk test) and graphical methods (i.e., histograms and quantile-
quantile plots) were used to test for normality. If the distribution
of the metabolite was not normal, a log transformation was
performed to meet the assumptions of a parametric test.
Mixed-effects linear regression models were used to test for
differences in child characteristics and plasma metabolites be-
tween nonobese and obese children, with adjustment for sex, age,
and Tanner stage, as needed, and by accounting for the non-
independence of related children within families. A Bonferroni
correction was applied to the metabolomic data to counteract the
problem of multiple comparisons; P , 1.151 3 1024 was
considered statistically significant.
A random forest analysis, which is a supervised classification
technique that is based on an ensemble of decision trees, was used
to classify nonobese and obese children. For a given decision tree,
a random subset of data with identifying true class information
was selected to build the tree (training set), and the remaining
data were passed down the tree to obtain a class prediction for
each sample repeatedly. The prediction accuracy was an unbiased
estimate of how well the sample class in a new data set could be
predicted. The mean decrease accuracy was used to determine
which metabolites made the largest contribution to the classifi-
cation. The mean decrease accuracy was determined by randomly
permuting a variable, running observed values through the trees,
and reassessing the prediction accuracy.
A principal components analysis (PCA), which is an un-
supervised linear mixture model aimed at accounting for the
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variance within a data set by a smaller number of mutually
uncorrelated PCs, was performed on the 304 log-transformed
metabolites. In our application, the PCs were vectors of me-
tabolite contributions. An orthogonal varimax rotation was used,
and factors with eigenvalues .1.0 were retained. Component
scores for each participant were calculated by using the stan-
dardized scoring coefficient. Metabolites with component load-
ing values with magnitudes that were $0.50 were retained for
a given component. The PCA was performed with the Proc
Factor and Proc Score procedures in SAS software (version 9.4;
SAS Institute Inc.) Mixed-effects linear regression models were
used to test the effect of the 20 PCs on selected phenotypes, with
adjustment for age, sex, Tanner staging, and obesity status.
Statistical analyses were performed in the SAS software and
STATA software (version13; StataCorp).
RESULTS
Global metabolomic profiling was performed in 803 Hispanic
children (405 boys and 398 girls; mean 6 SD age: 11.1 6 3.9 y;
age range: 4–19 y). This cohort was highly enriched for obesity
with 56% of children classified as obese (BMI$95th percentile)
according to CDC criteria (21). The remaining children were
nonobese with 16% classified as overweight and 28% classified
as normal weight. Fasting metabolites and hormones shown in
Table 1 differed significantly between nonobese and obese
children except for nonesterified fatty acids (NEFAs) and cor-
tisol. Fasting insulin concentrations and HOMA-IR were ele-
vated in obese children. When adjusted for age, sex, Tanner
stage, FFM, and FM, 24-h total energy expenditure (TEE) did
not differ by obesity status. When adjusted for age, sex, Tanner
stage, and energy balance, the TEE RQ and net fat oxidation
over the 24-h did not differ by obesity status; however, the sleep
RQ was slightly lower in obese than in nonobese children.
A summary of the 38 AAs, peptides, and their metabolites that
differed significantly between nonobese and obese children is
presented in Table 2. When adjusted for sex, age, and Tanner
stage, BCAAs (Leu, Ile, and Val) were significantly higher in
obese children as were BCAA catabolites 2-methylbutyrylcarnitine,
3-methyl-2-oxobutyrate, and isovalerylcarnitine. In addition,
propionylcarnitine and butyrylcarnitine, which are carnitine con-
jugates of propionyl-CoA and butyryl-CoA, were significantly el-
evated (Table 3). Additional AAs (alanine, glutamate, lysine,
phenylalanine, and tyrosine), polyamines, several g-glutamyl
dipeptides, and polypeptides were also elevated in obese chil-
dren. In contrast, levels of asparagine, aspartate, glycine, serine,
and histidine were lower in obese children. Notably, there were
significantly higher levels of a-hydroxybutyrate (AHB) and
a-ketobutyrate (AKB) in obese children.
TABLE 1
Characterization of the nonobese and obese Hispanic children1
Nonobese Obese Test Covariates Adjusted P
n 353 450 — —
Sex, M/F, n 163/190 242/208 Chi square — 3.1 3 1022
Age, y 11.09 6 4.402 11.04 6 3.52 t — 8.6 3 1021
Tanner stage 2.24 6 1.44 2.15 6 1.28 t — 3.9 3 1021
Anthropometric measures/body
composition
Weight, kg 41.74 6 18.78 67.30 6 27.55 Mixed effects Sex, age, Tanner stage 1.0 3 10232
BMI, kg/m2 19.94 6 3.78 30.07 6 6.70 Mixed effects Sex, age, Tanner stage 1.0 3 10232
BMI z score 0.64 6 0.76 2.31 6 0.38 Mixed effects Sex, age, Tanner stage 1.0 3 10232
FFM, kg 30.43 6 13.78 39.61 6 14.61 Mixed effects Sex, age, Tanner stage 1.0 3 10232
FM, kg 11.36 6 6.48 26.58 6 11.43 Mixed effects Sex, age, Tanner stage 1.0 3 10232
FM, % of weight 0.26 6 0.07 0.39 6 0.06 Mixed effects Sex, age, Tanner stage 1.0 3 10232
Fasting biochemistry
Glucose, mg/dL 90.63 6 9.57 94.38 6 14.02 Mixed effects Sex, age, Tanner stage 2.2 3 1027
Insulin, mU/mL 13.11 6 8.53 31.41 6 21.26 Mixed effects Sex, age, Tanner stage 1.0 3 10232
HOMA-IR 3.01 6 2.49 7.46 6 5.67 Mixed effects Sex, age, Tanner stage 1.0 3 10232
Leptin, mg/L 8.98 6 7.90 26.22 6 14.89 Mixed effects Sex, age, Tanner stage 1.0 3 10232
Triacylglycerol, mg/dL 87.77 6 46.62 124.27 6 61.78 Mixed effects Sex, age, Tanner stage 1.0 3 10232
HDL cholesterol, mg/dL 50.85 6 12.12 43.66 6 9.70 Mixed effects Sex, age, Tanner stage 1.0 3 10232
LDL cholesterol, mg/dL 99.98 6 28.65 106.74 6 29.74 Mixed effects Sex, age, Tanner stage 1.3 3 1023
Uric acid, mg/dL 4.57 6 1.36 5.92 6 1.75 Mixed effects Sex, age, Tanner stage 1.0 3 10232
CRP, mg/L 651.53 6 909.37 1761 6 1680 Mixed effects Sex, age, Tanner stage 1.0 3 10232
ALT, U/L 16.27 6 12.73 31.44 6 30.25 Mixed effects Sex, age, Tanner stage 1.0 3 10232
NEFAs, mEq/L 0.51 6 0.25 0.53 6 0.18 Mixed effects Sex, age, Tanner stage 1.0 3 1024
Cortisol, mg/L 66.32 6 30.04 63.33 6 30.51 Mixed effects Sex, age, Tanner stage 1.3 3 1021
Calorimetry
TEE, kcal/d 1826 6 380 2293 6 495 Mixed effects Sex, age, Tanner stage, FFM, FM 4.8 3 1021
Fat oxidation, % of nonprotein TEE 40.50 6 11.60 41.67 6 10.51 Mixed effects Sex, age, Tanner stage, FFM, FM 4.0 3 1021
24-h RQ 0.87 6 0.03 0.87 6 0.03 Mixed effects Sex, age, Tanner stage, energy balance 3.4 3 1021
Sleep RQ 0.85 6 0.03 0.84 6 0.03 Mixed effects Sex, age, Tanner stage, energy balance 4.1 3 1023
1For tests, “mixed effects” denotes mixed-effects linear regression models. ALT, alanine aminotransferase; CRP, C-reactive protein; FFM, fat-free mass;
FM, fat mass; NEFA, nonesterified fatty acid; RQ, respiratory quotient; TEE, total energy expenditure.
2Mean 6 SD (all such values).
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Consistent with elevated C-reactive protein concentrations,
several metabolites indicative of inflammation and the activation
of an immune response were elevated in the obese children.
Bradykinin (a potent vasodilator), bradykinin-des-Arg(9) (an active
metabolite of bradykinin), and HWESASLLR and HWESASXX
(peptides that map to complement C3 protein) were elevated in
obese children, consistent with the activation of an immune re-
sponse. Kynurenine and kynurenate, which are involved with the
TABLE 2
Global metabolomic profiling of amino acid metabolism of Hispanic children by obesity status1
Superpathway/subpathway and metabolites
Scaled, imputed values Adjusted results2
Nonobese Obese t (reference nonobese) P
Alanine and aspartate
Alanine 0.98 6 0.29 1.07 6 0.29 4.83 1.8 3 1026
Asparagine 1.10 6 0.30 0.95 6 0.25 26.69 5.8 3 10211
Aspartate 1.06 6 0.25 0.99 6 0.21 24.2 3.1 3 1025
Creatine
Creatine 0.94 6 0.28 1.02 6 0.26 4.43 1.1 3 1025
Glutamate
Glutamate 1.19 6 1.29 1.52 6 1.45 7.32 9.1 3 10213
Pyroglutamine 1.45 6 1.20 1.19 6 0.81 24.87 1.5 3 1026
Glycine, serine, and threonine
Glycine 1.15 6 0.27 0.94 6 0.23 210.86 5.6 3 10225
N-Acetylglycine 1.49 6 0.90 1.00 6 0.60 210.28 9.4 3 10223
Serine 1.11 6 0.25 0.95 6 0.21 28.82 1.7 3 10217
Histidine
Histidine 1.03 6 0.12 0.97 6 0.14 26.61 9.4 3 10211
Leucine, isoleucine, and valine
C5 0.96 6 0.25 1.08 6 0.26 6.59 1.1 3 10210
3-Methyl-2-oxobutyrate 0.97 6 0.20 1.04 6 0.19 4.93 1.1 3 1026
a-Hydroxyisovalerate 1.00 6 0.34 1.11 6 0.40 4.39 1.4 3 1025
Isoleucine 0.95 6 0.16 1.04 6 0.15 8.83 1.5 3 10217
C5-OH 0.92 6 0.32 1.16 6 0.40 9.47 9.2 3 10220
Leucine 0.96 6 0.16 1.04 6 0.14 8.78 2.2 3 10217
Valine 0.95 6 0.14 1.05 6 0.13 11.24 1.8 3 10226
Lysine
Lysine 0.96 6 0.19 1.03 6 0.18 6.38 3.8 3 10210
Methionine, cysteine, SAM, and taurine
AHB 1.01 6 0.46 1.10 6 0.37 4.43 1.1 3 1025
AKB 0.94 6 0.56 1.24 6 0.67 6.54 1.5 3 10210
3-(4)-Hydroxyphenyl lactate 0.97 6 0.30 1.09 6 0.30 7.61 1.3 3 10213
Phenylalanine and tyrosine
Phenylalanine 0.95 6 0.12 1.04 6 0.13 11.67 3.5 3 10228
Tyrosine 0.90 6 0.15 1.10 6 0.18 17.7 1.0 3 10232
Acisoga 0.96 6 0.26 1.07 6 0.27 5.26 2.1 3 1027
Polyamine
C-glycosyltryptophan 0.97 6 0.15 1.04 6 0.15 7.65 9.6 3 10214
Kynurenate 0.82 6 0.37 0.98 6 0.36 6.48 2.1 3 10210
Kynurenine 0.95 6 0.21 1.08 6 0.23 8.96 5.5 3 10218
Tryptophan 0.98 6 0.16 1.03 6 0.15 5.26 2.1 3 1027
Citrulline 1.05 6 0.24 0.97 6 0.21 24.49 8.6 3 1026
Urea cycle; arginine and proline
Ornithine 0.99 6 0.38 1.13 6 0.45 5.37 1.2 3 1027
Peptide
g-Glutamylglutamate 1.03 6 1.10 1.22 6 1.04 5.01 7.3 3 1027
g-Glutamyl amino acid
g-Glutamylleucine 1.09 6 0.65 1.19 6 0.65 3.86 1.3 3 1024
g-Glutamylphenylalanine 0.97 6 0.24 1.09 6 0.26 7.38 6.3 3 10213
g-Glutamyltyrosine 0.92 6 0.23 1.12 6 0.28 11.73 1.9 3 10228
Bradykinin 1.17 6 2.05 2.32 6 5.85 6.67 6.5 3 10211
Polypeptide
Bradykinin-des-Arg(9) 0.89 6 1.40 2.05 6 6.65 7.32 9.4 3 10213
HWESASLLR 1.62 6 3.04 2.53 6 6.17 5.24 2.4 3 1027
HWESASXX 1.04 6 0.77 1.50 6 1.81 5.72 1.7 3 1028
1All values are means 6 SDs. Main effect of obesity status, P , 1.151 3 1024. AHB, a-hydroxybutyrate; AKB,
a-ketobutyrate; C5, 2-methylbutyrylcarnitine; C5-OH, isovalerylcarnitine; SAM, S-adenosylmethionine.
2Mixed-effects linear regression model adjusted for age, sex, and Tanner stage (ln metabolite).
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dilation of blood vessels during inflammation, were elevated in obese
children. In contrast, 1-acyl-lysolipids and 2-acyl-lysolipids (Table 3),
which are involved in innate immunity, were generally decreased.
A summary of the 52 lipid metabolites that differed signifi-
cantly between nonobese and obese children is presented in Table
3. Carnitine and the short-chain acylcarnitines [propionylcarnitine
TABLE 3
Global metabolomic profiling of lipid metabolism of Hispanic children by obesity status1
Superpathway/subpathway and metabolites
Scaled, imputed values Adjusted results2
Nonobese Obese t (reference nonobese) P
Carnitine
Carnitine 0.94 6 0.14 1.04 6 0.13 10.71 2.3 3 10224
Acylcarnitine
Propionylcarnitine (3) 0.92 6 0.23 1.10 6 0.25 10.78 1.2 3 10224
Butyrylcarnitine (4) 1.03 6 0.66 1.30 6 0.71 8.2 1.8 3 10215
Hexanoylcarnitine (6) 1.01 6 0.48 1.10 6 0.32 5.59 3.5 3 1028
Stearoylcarnitine (18) 1.07 6 0.43 0.87 6 0.36 26.37 4.2 3 10210
Oleoylcarnitine (18:1) 1.20 6 0.52 1.01 6 0.39 25.57 4.1 3 1028
Fatty acid, amide
2-Aminoheptanoate 1.01 6 0.40 1.11 6 0.44 4.47 9.5 3 1026
2-Aminooctanoate 1.29 6 0.77 1.03 6 0.66 26.30 6.4 3 10210
Fatty acid, dicarboxylate
Dodecanedioate 1.25 6 2.24 0.92 6 0.52 24.23 2.7 3 1025
Tetradecanedioate 1.60 6 3.96 1.04 6 0.85 23.84 1.4 3 1024
2-Hydroxydecanoate 1.14 6 0.46 1.00 6 0.34 24.89 1.3 3 1026
Ketone bodies
BHBA 3.42 6 7.69 1.73 6 3.17 26.10 2.0 3 1029
Long-chain fatty acid
10-Heptadecenoate (17:1n–7) 1.03 6 0.55 1.12 6 0.44 5.00 7.9 3 1027
Arachidate (20:0) 1.19 6 0.48 1.00 6 0.28 24.99 8.3 3 1027
Myristoleate (14:1n–5) 1.04 6 0.72 1.12 6 0.55 5.61 3.3 3 1028
Nonadecanoate (19:0) 1.15 6 0.44 0.99 6 0.28 26.88 1.6 3 10211
Palmitoleate (16:1n–7) 1.00 6 0.60 1.13 6 0.48 6.59 1.1 3 10210
Lysolipid
1-Arachidonoylglycerophosphocholine (20:4n–6) 1.11 6 0.34 0.98 6 0.38 26.38 3.9 3 10210
1-Dihomo-linoleoylglycerophosphocholine (20:2n–6) 1.14 6 0.76 0.94 6 0.74 24.53 7.2 3 1026
1-Docosahexaenoylglycerophosphocholine (22:6n–3) 1.17 6 0.50 1.01 6 0.42 25.25 2.2 3 1027
1-Docosapentaenoylglycerophosphocholine (22:5n–3) 1.10 6 0.44 0.99 6 0.43 23.7 2.4 3 1024
1-Eicosenoylglycerophosphocholine (20:1n–9) 1.14 6 0.92 0.85 6 0.71 26.17 1.4 3 1029
1-Linolenoylglycerophosphocholine (18:3n–3) 1.22 6 0.58 1.01 6 0.48 25.31 1.6 3 1027
1-Linoleoylglycerophosphocholine (18:2n–6) 1.16 6 0.28 0.92 6 0.23 212.62 1.0 3 10232
1-Linoleoylglycerophosphoethanolamine 1.10 6 0.37 0.98 6 0.32 24.97 8.9 3 1027
1-Margaroylglycerophosphocholine (17:0) 1.32 6 1.03 1.05 6 1.02 24.23 2.8 3 1025
1-Oleoylglycerophosphocholine (18:1) 1.24 6 0.55 0.97 6 0.49 28.33 6.7 3 10216
1-Oleoylglycerophosphoethanolamine 1.19 6 0.44 1.01 6 0.36 25.98 4.2 3 1029
1-Palmitoylglycerophosphoinositol 1.01 6 0.76 1.20 6 0.68 6.18 1.3 3 1029
1-Stearoylglycerophosphocholine (18:0) 1.35 6 0.90 1.17 6 0.89 24.27 2.3 3 1025
2-Linoleoylglycerophosphocholine 1.25 6 0.44 0.93 6 0.30 212.18 3.0 3 10230
2-Linoleoylglycerophosphoethanolamine 1.05 6 0.44 0.86 6 0.38 25.82 1.0 3 1028
2-Oleoylglycerophosphocholine 1.22 6 0.51 0.96 6 0.40 28.49 2.1 3 10216
2-Oleoylglycerophosphoethanolamine 1.13 6 0.48 0.94 6 0.41 25.28 1.9 3 10207
2-Palmitoylglycerophosphocholine 1.22 6 0.59 1.09 6 0.59 24.05 5.9 3 10205
2-Stearoylglycerophosphocholine 1.38 6 1.00 1.21 6 1.14 23.71 2.3 3 10204
Medium-chain fatty acid
Caprate (10:0) 1.16 6 0.49 0.99 6 0.29 25.08 5.2 3 10207
Laurate (12:0) 1.28 6 0.81 1.05 6 0.50 24.15 3.8 3 10205
Monoacylglycerol
1-Palmitoylglycerol (1-monopalmitin) 0.98 6 0.29 1.08 6 0.35 4.08 5.1 3 10205
Phospholipid
Choline 0.96 6 0.19 1.05 6 0.19 6.90 1.4 3 10211
PUFA
Dihomo-linolenate (20:3n–3 or n–6) 1.00 6 0.43 1.14 6 0.48 6.57 1.2 3 10210
Secondary bile acid
Taurolithocholate 3-sulfate 1.22 6 1.22 0.95 6 0.96 24.50 8.3 3 10206
Sphingolipid
Stearoylsphingomyelin 0.96 6 0.29 1.07 6 0.33 5.11 4.5 3 1027
(Continued)
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(3), butyrylcarnitine (4), and hexanoylcarnitine (6)] were ele-
vated in obese children, whereas a few of the long-chain
acylcarnitines [stearoylcarnitine (18) and oleoylcarnitine
(18:1)] were lower. There was a striking decrease in lysolipids
(glycerophosphocholines and glycerophosphoethanolamines) and
dicarboxylated fatty acids (dodecanedioate, tetradecanedioate,
and 2-hydroxydecanoate) in obese children. The ketone body
b-hydroxybutyrate was significantly lower in obese children
than in nonobese children. With the exceptions of cortisone,
androsterone sulfate, and epiandrosterone sulfate, steroid de-
rivatives were markedly higher in obese children. Consistent
with elevated LDL-cholesterol concentrations in obese children,
the cholesterol precursor lathosterol was significantly higher in
obese children.
A summary of carbohydrate and nucleotide metabolites that
differed significantly between nonobese and obese children is pre-
sented in Table 4. Mannose and pyruvate were higher, but glycerate
was lower, in obese children than in nonobese children. In the tri-
carboxylic acid (TCA) cycle, the only metabolite that reached
significance was citrate, which was lower in obese children.
Consistent with elevated uric acid, higher levels of purine and
pyrimidine metabolites were seen in obese children. Levels of the
purine catabolite xanthine were significantly elevated, which may
have reflected an increased generation of H2O2 during the
conversion of hypoxanthine to xanthine by xanthine oxidase as
part of an inflammatory response. Xanthine oxidase also con-
verts xanthine to urate, the levels of which were also higher in
the obese-children group.
To assess the predictive accuracy of classifying children by
obesity status, a random forest analysis was performed on the
metabolites. Tyrosine was the highest-ranked metabolite on the
basis of its contribution to the obesity classification. The top-
ranked metabolites were from all the major pathways (Figure 1).
The predictive accuracy for obesity classification was 81%.
A PCAwas used to reduce the large number of metabolites to
fewer clusters of highly correlated metabolites. The PCA con-
solidated the 304 metabolites into 65 PCs with eigenvalues .1
and factor loading values with magnitudes $0.50 These 65 PCs
explained 75.6% of the variance in the data set. On the basis of
a scree plot, the first 20 PCs with eigenvalues .2.5 were re-
tained and explained 53.4% of the variance (Table 5). These 20
PCs were comprised of 161 of 304 metabolites.
First, we tested which of the 20 PCs were associated with BMI
and adiposity. Six PCs (PC3, PC4, PC6, PC10, PC12, and PC18)
were associated with BMI and accounted for 46% of the variance in
BMI, with PC6 (BCAA and aromatic AA) and PC10 (asparagine,
glycine, and serine) making the largest contributions (Table 6).
Eight PCs (PC3, PC4, PC6, PC9, PC10, PC12, PC18, and PC19)
were associated with adiposity (percentage of FM) and accounted
for 36% of the variance, with PC10 and PC12 (acylcarnitines)
making the largest contributions.
Next, we tested which of the 20 PCs were associated with
metabolic risk factors, energy expenditure, and fat oxidation.
Metabolic risk factors for insulin resistance, hyperleptinemia,
hypertriglyceridemia, hyperuricemia, and inflammation
(C-reactive protein) were predicted by many of the same PCs as
for BMI and the percentage of FM, namely PC6, PC9, and PC10.
The TEE was also associated with PC6, PC9, and PC10 after
adjustment for age, sex, Tanner stage, obesity status, FFM, and
FM. Fasting NEFAs correlated highly with PC1 (AHB and lipids)
and PC3 (glycerophosphocholines). Fat oxidation and sleep RQ
were inversely related to PC8 (glycerophosphoethanolamines)
and positively related to PC16 (acylcarnitines), independent of
age, sex, Tanner staging, obesity status, and energy balance.
DISCUSSION
Global metabolomic profiling revealed different patterns of
AAs, lipids, carbohydrate, and nucleotide intermediary metabo-
lism between obese Hispanic children and their nonobese siblings
indicative of insulin resistance, increased BCAA catabolism,
mitochondrial dysfunction, reduced fatty acid b-oxidation, in-
creased oxidative stress and inflammation, and altered steroid
metabolism. The obesity-related increases in AAs, acylcarnitines,
lysolipids, and nucleotides are largely concordant with those in
adult studies; however, increased steroid metabolites may be
unique to children with obesity. The use of calorimetry has not
supported metabolic inflexibility in obese children, but there may
be a metabolic cost to maintain homeostasis through the activation
of alternative intermediary pathways. Insulin resistance, hyper-
leptinemia, hypertriglyceridemia, hyperuricemia, and oxidative
stress and inflammation were evident in obese children.
TABLE 3 (Continued )
Superpathway/subpathway and metabolites
Scaled, imputed values Adjusted results2
Nonobese Obese t (reference nonobese) P
Steroid
4-Androsten-3b-17b-diol disulfate 1 1.12 6 1.19 1.51 6 1.24 11.31 9.4 3 10227
4-Androsten-3b-17b-diol disulfate 2 1.01 6 0.71 1.17 6 0.65 8.55 1.3 3 10216
5a-Androstan-3b-17b-diol disulfate 1.08 6 1.44 1.24 6 1.30 7.18 2.3 3 10212
Androsteroid monosulfate 2 1.23 6 1.29 1.43 6 1.27 6.60 1.0 3 10210
Androsterone sulfate 1.40 6 1.50 1.34 6 1.09 24.50 8.5 3 1026
Cortisone 1.06 6 0.20 0.96 6 0.21 26.64 7.6 3 10211
DHEA-S 1.15 6 1.04 1.28 6 0.92 7.42 4.6 3 10213
Epiandrosterone sulfate 1.34 6 1.50 1.29 6 1.08 24.70 3.4 3 1026
Sterol
Lathosterol 0.65 6 0.42 1.16 6 0.59 15.38 1.0 3 10232
1All values are means 6 SDs. Main effect of obesity status, P , 1.151 3 1024. BHBA, b-hydroxybutyrate; DHEA-S, dehydroisoandrosterone sulfate.
2Mixed-effects linear regression model adjusted for age, sex, and Tanner stage (ln metabolite).
METABOLOMICS IN CHILDHOOD OBESITY 261
The PCA linked correlated metabolites to clinical biomarkers
of obesity and metabolic risk. Of the first 20 PCs, 8 PCs were
associated with BMI or adiposity. PC6 (BCAAs and aromatic
AAs), PC9 (aspartate, dipeptides, and citrate), and PC10 (as-
paragine, glycine, and serine) were associated with risk factors
for insulin resistance, hyperleptinemia, hypertriglyceridemia,
FIGURE 1 Random forest plot of top-ranked metabolites with the highest MDA for the classification of nonobese and obese Hispanic children.
TABLE 4
Global metabolomic profiling of carbohydrate and nucleotide metabolism of Hispanic children by obesity status1
Superpathway/subpathway and metabolites
Scaled, imputed values Adjusted results2
Nonobese Obese t (reference nonobese) P
Carbohydrate
Mannose 0.91 6 0.22 1.11 6 0.29 13.22 1.0 3 10232
Glycolysis, gluconeogenesis, and pyruvate
Glycerate 1.07 6 0.36 0.98 6 0.36 23.81 1.5 3 1024
Pyruvate 0.95 6 0.42 1.15 6 0.49 5.02 7.2 3 1027
Pentose metabolism
Bilirubin (E-E) 1.37 6 0.99 1.08 6 0.75 24.35 1.6 3 1025
Nicotinate
N1-Methyl-2-pyridone-5-carboxamide 0.87 6 0.37 1.15 6 0.48 8.37 5.0 3 10216
Pantothenate and CoA
Pantothenate 0.96 6 0.28 1.09 6 0.27 7.85 2.3 3 10214
Tocopherol
g-Tocopherol 0.93 6 0.35 1.13 6 0.42 8.76 2.6 3 10217
TCA3 cycle
Citrate 1.10 6 0.29 0.96 6 0.21 28.21 1.7 3 10215
Purine metabolism, (hypo)xanthine/inosine
Urate 0.92 6 0.19 1.10 6 0.24 13.24 1.0 3 10232
Xanthine 0.97 6 0.37 1.17 6 0.48 5.94 5.2 3 1029
Purine metabolism, adenine
N6-Carbamoylthreonyladenosine 0.93 6 0.25 1.03 6 0.23 5.48 6.6 3 1028
N2-N2-Dimethylguanosine 0.93 6 0.31 1.02 6 0.29 5.27 1.9 3 1027
Pyrimidine metabolism, uracil
5-Methyluridine (ribothymidine) 1.10 6 0.69 0.96 6 0.23 26.84 2.1 3 10211
N-Acetyl-b-alanine 1.00 6 0.35 1.10 6 0.35 5.03 6.8 3 1027
Pseudouridine 0.97 6 0.11 1.03 6 0.12 7.39 5.7 3 10213
1All values are means 6 SDs. Main effect of obesity status, P , 1.151 3 1024.
2Mixed-effects linear regression model, adjusted for sex, age, and Tanner stage (ln metabolite).
3TCA, tricarboxylic acid.
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TABLE 5
PC analysis1







1 Amino acid and lipid (37) Amino acid: a-hydroxybutyrate 39.00 12.83 12.83
Lipid: acetylcarnitine, 15-methylpalmitate, 17-methylstearate, hexadecanedioate,
tetradecanedioate, 16-hydroxypalmitate, 3-hydroxydecanoate, 3-hydroxyoctanoate,
glycerol, 3-hydroxybutyrate, 10-heptadecenoate, 10-nonadecenoate,
arachidate, cis-vaccenate, eicosenoate, margarate, myristate, myristoleate,
nonadecanoate, oleate, palmitate, palmitoleate, pentadecanoate, stearate,
5-dodecenoate, caprate, laurate, dihomo-linoleate, docosadienoate,
docosahexaenoate, docosapentaenoate, docosapentaenoate, linoleate,
linolenate, stearidonate
2 Amino acid and lipid (14) Amino acid: glutamate, glutamine, 5-oxoproline 20.28 6.67 19.50
Lipid: leukotriene B4, 13-HODE plus 9-HODE, glycerol 3-phosphate,
1-oleoylplasmenylethanolamine, 1-palmitoylplasmenylethanolamine,
glycerophosphorylcholine, arachidonate, dihomo-linolenate, eicosapentaenoate,
sphingosine, leucylleucine











4 Steroid (12) Steroid: 21-hydroxypregnenolone disulfate, 4-androsten-3b-17b-diol disulfate 1,
4-androsten-3b-17b-diol disulfate 2, 5a-androstan-3b-17b-diol disulfate,
5a-pregnan-3b-20a-diol disulfate, andro steroid monosulfate 2, androsterone
sulfate, dehydroisoandrosterone sulfate, epiandrosterone sulfate, pregn steroid
monosulfate, pregnen-diol disulfate, pregnenolone sulfate
13.30 4.37 29.10
5 g-Glutamyl amino acid
(7)




6 Amino acid: BCAAs and
aromatic AAs (7)
Amino acid: isoleucine, leucine, lysine, methionine, phenylalanine, tyrosine,
g-glutamyltyrosine
7.21 2.37 34.93
7 Amino acid (3) Amino acid: 3-methyl-2-oxobutyrate, 3-methyl-2-oxovalerate, 4-methyl-
2-oxopentanoate
6.35 2.09 37.02






9 Amino acid and TCA (7) Amino acid: aspartate, isoleucylglycine, valylglycine, dimethylarginine,
pro-hydroxy-pro, trans-4-hydroxyproline; TCA cycle: citrate
5.06 1.67 40.67
10 Amino acid (3) Amino acid: asparagine, glycine, serine 4.58 1.51 42.18
11 Vitamin and lipid (5) Vitamin: a-Tocopherol, 1-stearoylglycerol, palmitoyl sphingomyelin, stearoyl
sphingomyelin, cholesterol
4.47 1.47 43.65
12 Amino acid: shorter-
chain acylcarnitines
(5)
Amino acid–acylcarnitines: 2-methylbutyrylcarnitine, isovalerylcarnitine Lipid:
carnitine, butyrylcarnitine, propionylcarnitine
4.31 1.42 45.07
13 Amino acid, glycogen,
vitamin, and
nucleotide (5)
Amino acid: serotonin; glycogen metabolism: maltose, maltotriose; vitamin:
nicotinamide; nucleotide: adenosine 5-monophosphate
4.06 1.34 46.40
14 Lipid: cholates (4) Lipid: glycochenodeoxycholate, glycocholate, taurochenodeoxycholate,
taurocholate
3.49 1.15 47.55
15 Peptide (5) Peptide: glycylleucine, leucylalanine, leucylglycine, serylleucine, threonylleucine 3.40 1.12 48.67
16 Lipid, longer-chain
acylcarnitines (5)
Lipid: cis-4-decenoyl carnitine, decanoylcarnitine, hexanoylcarnitine,
laurylcarnitine, octanoylcarnitine
3.17 1.04% 49.71%
17 Lipid (4) Lipid: azelate, sebacate, caproate, heptanoate 3.03 1.00 50.71
(Continued)
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hyperuricemia, and inflammation. PC12 (shorter-chain acylcarnitines)
made a large contribution to BMI, adiposity, and leptin but
not to metabolic risk factors. PC1 (AHB and lipids) and PC3
(lysolipids- glycerophosphocholines) were associated with
NEFAs. PC8 (lysolipids) was negatively related to fat oxidation,
and PC16 (longer-chain acylcarnitines) was positively related to
fat oxidation.
Insulin resistance
Along with elevated glucose and insulin concentrations, higher
levels of AHB and lower levels of 1-linoleoylglycerophosphocholine
and 2-linoleoylglycerophosphocholine were associated with
insulin resistance in obese children in concordance with adult
studies (22, 23). Mannose, which is an essential monosaccharide
constituent of glycoproteins and glycolipids, was also elevated in
obese children. In individuals with diabetes, plasma mannose
levels are high, and levels of mannose and glucose are positively
correlated (24).
Increased BCAA catabolism
Increased circulating BCAAs also reflected insulin resistance
in obese Viva la Familia Study children. In our PCA, BCAAs and
aromatic AAs formed a cluster (PC6), and the by-products of
BCAA catabolism (C3 and C5 acylcarnitines) formed another
cluster (PC12). Increased BCAA catabolism may be due to in-
creased dietary consumption or alterations in skeletal muscle
protein turnover, energy metabolism, andmitochondrial function.
Elevated levels of circulating BCAAs, propionylcarnitine, and
isovalerylcarnitinewere proposed as markers of insulin resistance
and diabetes risk in obese adults (2, 3), but the elevation of other
AAs such as Phe, Tyr, and sulfur-containing AA were also
consistently reported (25) as in our study.
Mitochondrial dysfunction
With the increased catabolism of BCAAs, AHB may be
generated from AKB. Under conditions where propionyl-CoA
cannot enter the TCA cycle or that result in the accumulation of
NADH, the metabolism of AKB may shift to the production of
AHB. In this study, AHB accumulation may have reflected a
limited TCA capacity or demand relative to available substrate.
This hypothesis was supported by significantly elevated levels
of propionylcarnitine, which is a surrogate marker for propionyl-
CoA levels as well as elevated levels of pyruvate, which sug-
gested the reduced conversion of pyruvate to acetyl-CoA. In
addition, the TCA-cycle intermediate citrate was signifi-
cantly lower in obese children than in nonobese children. In the
first step of the TCA cycle, oxaloacetate and acetyl-CoA
combine to form citrate, which is shuttled out of the mito-
chondria to the cytosol where the acetyl-CoA moiety is con-
verted to malonyl-CoA for fatty acid synthesis. The lower
citrate perhaps reflects increased rates of fatty acid synthesis,
resulting in the higher palmitate and triacylglycerol in obese
children.
Oxidative stress also may contribute to elevated AHB levels in
obese children because the increased synthesis of cysteine, which
is a key component of the antioxidant glutathione, produces AKB
as a byproduct. We previously showed higher plasma total
cysteine and lower total glutathione in these obese children than
in their nonobese siblings (26). Together with the described al-
terations in BCAA catabolism, these changes are indicative of
mitochondrial dysfunction in obese children.
Reduced fatty acid b oxidation
Despite higher levels of long-chain fatty acids, levels of the
long-chain acylcarnitines stearoylcarnitine, and oleoylcarnitine,
which are generated during the import of long-chain fatty acids
into themitochondria for catabolism, were significantly lower in the
obese-children group. Levels of lysolipids (glycerophosphocholines
and glycerophosphoethanolamines) and dicarboxylate fatty
acids, which ware intermediates generated during v-oxidation,
also were lower. Reduced lysophosphatidylcholines (18:1, 18:2,
and 20:4) were reported previously in obese children (9). Levels
of 3-hydroxy fatty acid (a readout of b oxidation) also tended to
be lower in obese children. There was no evidence of ketogenesis
because b-hydroxybutyrate was lower in the obese-children
group. In contrast to findings in obese adults of overloading the
mitochondria with lipid substrates leading to incomplete fatty acid
oxidation (3), these changes in obese children do not suggest an
excessive fatty acid supply or dysfunctional b-oxidation but, in-
stead, represent a strong signature of the reduced catabolism of
fatty acids.
Metabolic flexibility: appropriate fuel use
Respiratory calorimetry did not reveal any significant differ-
ences in the 24-h RQ or net fat use between obese and nonobese
children (27). The sleep RQ, which is reflective of the fasting
TABLE 5 (Continued )







18 Amino acid (4) Amino acid: isobutyrylcarnitine, p-cresol sulfate, phenylacetylglutamine,
3-indoxyl sulfate
2.80 0.92 51.63




20 Amino acid (3) Amino acid: a-hydroxyisovalerate, 3-(4-hydroxyphenyl)lactate, indolelactate 2.62 0.86 53.38
1PC analysis was used to identify the top 20 PCs with eigenvalues.2.5 comprised of 161 metabolites with factor loading values with magnitudes $0.50.
AA, amino acid; BCAA, branched-chain amino acid; GPC, glycerophosphocholine; GPE, glycerophosphoethanolamine; HODE, hydroxy-octadecadienoic
acid; PC, principal component; TCA, tricarboxylic acid.
264 BUTTE ET AL.
state, was actually lower in the obese-children group, which
indicated slightly higher net fat use. Although the net fuel use did
not differ, flux through metabolic pathways may have differed.
Intermediary metabolite interconversions do not affect the cal-
culation of nutrient use from respiratory gas measurements so
long as there is no accumulation or depletion of metabolites
TABLE 6
Mixed-effects linear regression models predicting child characteristics from metabolite PC1
b 6 SE F Standardized b PCs, partial R2 All, full R2 P
Anthropometric measures and body composition
BMI2 0.46 0.58
PC3 20.043 6 0.007 26.34 20.16 4.8 3 10210
PC4 0.044 6 0.010 4.63 0.17 4.6 3 1026
PC6 0.135 6 0.013 10.30 0.31 8.5 3 10223
PC10 20.135 6 0.012 211.43 20.26 3.5 3 10227
PC12 0.068 6 0.011 6.16 0.18 1.4 3 1029
PC18 20.040 6 0.009 24.64 20.10 4.5 3 1026
FFM2 0.45 0.84
PC3 20.034 6 0.006 25.20 20.08 2.8 3 1027
PC4 0.071 6 0.009 7.62 0.17 1.2 3 10213
PC5 0.156 6 0.013 12.32 0.23 1.0 3 10232
PC6 20.089 6 0.011 27.77 20.10 4.4 3 10214
PC7 0.034 6 0.011 3.23 0.05 1.3 3 1023
FM%2 0.36 0.42
PC3 20.046 6 0.009 25.34 20.16 1.4 3 1027
PC4 0.048 6 0.012 4.12 0.18 4.5 3 1025
PC6 0.089 6 0.016 5.39 0.20 1.1 3 1027
PC9 20.044 6 0.012 23.78 20.14 1.8 3 1024
PC10 20.140 6 0.015 29.38 20.27 2.2 3 10219
PC12 0.095 6 0.014 6.99 0.24 8.8 3 10212
PC18 20.048 6 0.011 24.55 20.13 6.7 3 1026
PC19 0.030 6 0.009 3.31 0.10 1.0 3 1023
Fasting biochemistries
HOMA-IR3 0.20 0.57
PC3 20.088 6 0.020 24.55 20.11 6.6 3 1026
PC6 0.337 6 0.039 10.24 0.31 1.4 3 10222
PC9 0.089 6 0.027 3.58 0.11 3.8 3 1024
PC10 20.303 6 0.037 28.72 20.23 3.5 3 10217
Leptin3 0.16 0.64
PC6 0.157 6 0.040 3.91 0.11 1.1 3 1024
PC9 20.088 6 0.027 23.25 20.09 1.2 3 1023
PC10 20.284 6 0.037 27.65 20.17 9.2 3 10214
PC11 0.081 6 0.027 2.97 0.06 3.1 3 1023
PC12 0.132 6 0.032 4.08 0.12 5.3 3 1025
PC19 0.079 6 0.022 3.64 0.08 3.0 3 1024
Triglycerides3 0.24 0.47
PC6 0.168 6 0.023 7.27 0.24 1.3 3 10212
PC8 0.155 6 0.014 11.32 0.31 8.9 3 10227
PC10 20.213 6 0.023 29.12 20.28 1.6 3 10218
PC11 0.087 6 0.017 5.04 0.14 6.4 3 1027
Uric acid3 0.12 0.48
PC4 0.046 6 0.012 3.84 0.17 1.4 3 1024
PC6 0.089 6 0.016 5.72 0.19 1.8 3 1028
PC9 0.062 6 0.011 5.49 0.17 6.3 3 1028
PC10 20.086 6 0.015 25.56 20.17 4.3 3 1028
CRP3 0.10 0.35
PC6 0.462 6 0.073 6.34 0.22 5.0 3 10210
PC9 20.256 6 0.054 24.74 20.18 2.7 3 1026
PC10 20.481 6 0.074 26.53 20.20 1.5 3 10210
ALT3 0.06 0.23
PC6 0.181 6 0.038 4.73 0.17 2.9 3 1026
PC14 0.108 6 0.024 4.45 0.16 1.0 3 1025
PC17 0.082 6 0.024 3.38 0.13 7.7 3 1024
NEFAs3 0.61 0.67
PC1 0.302 6 0.011 28.02 0.73 1.0 3 10232
PC3 0.033 6 0.010 3.45 0.08 5.9 3 1024
(Continued)
METABOLOMICS IN CHILDHOOD OBESITY 265
during the study period (28). With the use of stable isotopes and
calorimetry, obese adolescents were shown to adapt appropriately
to changes in carbohydrate and fat intakes (29, 30). However, to
maintain normal glucose and lipid concentrations, normal rates of
glucose production and lipolysis, and appropriate fuel use, obese
adolescents required a 2-fold increase in insulin secretion
compared with that of their lean counterparts. As in the Viva la
Familia Study, obese adolescents were highly insulin resistant
both in the overnight fasted state and in response to a glucose
challenge.
Inflammation accompanies obesity
Several metabolites [bradykinin and bradykinin-des-Arg(9),
complement C3 protein, kynurenine, and kynurenate] that are
indicative of inflammation and the activation of an immune
response were elevated in obese children. Also, xanthine, which
is a player in the inflammatory response, and urate, which is
a scavenger of oxidative species (31, 32), increased in obese
children.
Increased androgens in obese group
Elevated androgen derivatives, which are precursors of tes-
tosterone and estrogens, were observed in obese children. These
anabolic steroids may induce premature adrenarche, which was
linked to unfavorablemetabolic features including hyperinsulinism,
dyslipidemia, and later-appearing ovarian hyperandrogenism
(33). Indeed, our findings replicated those reported in 6–10 y-old
children in which an androgen pattern of higher levels of
dehydroisoandrosterone sulfate and its derivatives were associ-
ated with parent-reported sexual maturation (10).
Our metabolomic profiling corroborated findings in some (9,
10) but not all (8, 11) pediatric publications. Enhanced mito-
chondrial function and adaptive metabolic plasticity in obese
youth were inferred because of the lack of evidence of defective
fatty acid or AA metabolism in contrast with our results (8).
Increased plasma AA concentrations (BCAAs, Phe, Met, His,
Arg, Ser, Gly, and acylcarnitines) were positively associated with
b cell function relative to insulin sensitivity (11), again contrary
to our results. Lower acyl-alkyl phosphatidylcholines and lyso-
phosphatidylcholines were shown in obese children (9) in
agreement with our results. Higher levels of BCAAs (Val, Leu,
Ile, and related intermediates C3 and C5 acylcarnitines), an-
drogens, and large neutral AAs (Phe, Tyr, and Trp) in obese
children were in agreement with our findings (10). Discrep-
ancies in studies may be attributed to differences in sample
sizes, subject characteristics, and analytic platforms.
In conclusion, global metabolomics profiling in obese children
recapitulated the increased BCAA and acylcarnitine catabolism
and changes in nucleotides, lysolipids, and inflammation markers
seen in obese adults; however, a strong signature of reduced fatty
acid catabolism and increased steroid derivatives may be unique
to obese children. Metabolic flexibility in fuel use observed in
obese children may have occurred through the activation of
alternative intermediary pathways. Insulin resistance, hyper-
leptinemia, hypertriglyceridemia, hyperuricemia, and oxidative
stress and inflammation evident in obese children were associated
with distinct metabolomic profiles.
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